Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An autologous cell replacement therapy for insulin-dependent diabetic datients

Next Previous
Trial Profile

An autologous cell replacement therapy for insulin-dependent diabetic datients

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 06 May 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cell replacements (Primary)
  • Indications Type 1 diabetes mellitus
  • Focus First in man; Therapeutic Use

Most Recent Events

  • 06 May 2019 New trial record
  • 30 Apr 2019 According to the Orgenesis media release, Professor Naim Shehadeh is the principal investigator of this study.
  • 30 Apr 2019 According to the Orgenesis media release, the company announced that it has received Institutional Review Board (IRB) approval to collect liver biopsies from patients at Rambam Medical Center located in Haifa, Israel for this study. This study is expected to commence in May 2019.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top